Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Age-associated hydroxymethylation in human bone-marrow mesenchymal stem cells

  • Toraño, Estela G
  • Bayón, Gustavo F
  • del Real, Álvaro
  • Sierra, Marta I
  • García, María G
  • Carella, Antonella
  • Belmonte, Thalia
  • Urdinguio, Rocio G
  • Cubillo, Isabel
  • Garcia-Castro, Javier
  • Delgado-Calle, Jesús
  • Pérez-Campo, Flor M
  • Riancho, José A
  • Fraga, Mario F
  • Fernandez, Agustín F
BACKGROUND: Age-associated changes in genomic DNA methylation have been primarily attributed to 5-methylcytosine (5mC). However, the recent discovery of 5-hydroxymethylcytosine (5hmC) suggests that this epigenetic mark might also play a role in the process. METHODS: Here, we analyzed the genome-wide profile of 5hmc in mesenchymal stem cells (MSCs) obtained from bone-marrow donors, aged 2-89 years. RESULTS: We identified 10,685 frequently hydroxymethylated CpG sites in MSCs that were, as in other cell types, significantly associated with low density CpG regions, introns, the histone posttranslational modification H3k4me1 and enhancers. Study of the age-associated changes to 5hmC identified 785 hyper- and 846 hypo-hydroxymethylated CpG sites in the MSCs obtained from older individuals. CONCLUSIONS: DNA hyper-hydroxymethylation in the advanced-age group was associated with loss of 5mC, which suggests that, at specific CpG sites, this epigenetic modification might play a role in DNA methylation changes during lifetime. Since bone-marrow MSCs have many clinical applications, and the fact that the epigenomic alterations in this cell type associated with aging identified in this study could have associated functional effects, the age of donors should be taken into account in clinical settings.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Spatiotemporal Pattern of Doublecortin Expression in the Retina of the Sea Lamprey

  • Fernández López, Blanca
  • Romaus-Sanjurjo, Daniel
  • Senra Martínez, Pablo
  • Anadón Álvarez, Ramón
  • Barreiro Iglesias, Antón
  • Rodicio Rodicio, María Celina
Despite the importance of doublecortin (DCX) for the development of the nervous system, its expression in the retina of most vertebrates is still unknown. The key phylogenetic position of lampreys, together with their complex life cycle, with a long blind larval stage and an active predator adult stage, makes them an interesting model to study retinal development. Here, we studied the spatiotemporal pattern of expression of DCX in the retina of the sea lamprey. In order to characterize the DCX expressing structures, the expression of acetylated α-tubulin (a neuronal marker) and cytokeratins (glial marker) was also analyzed. Tract-tracing methods were used to label ganglion cells. DCX immunoreactivity appeared initially in photoreceptors, ganglion cells and in fibers of the prolarval retina. In larvae smaller than 100 mm, DCX expression was observed in photoreceptors, in cells located in the inner nuclear and inner plexiform layers (IPLs) and in fibers coursing in the nuclear and IPLs, and in the optic nerve (ON). In retinas of premetamorphic and metamorphic larvae, DCX immunoreactivity was also observed in radially oriented cells and fibers and in a layer of cells located in the outer part of the inner neuroblastic layer (INbL) of the lateral retina. Photoreceptors and fibers ending in the outer limitans membrane (OLM) showed DCX expression in adults. Some retinal pigment epithelium cells were also DCX immunoreactive. Immunofluorescence for α-tubulin in premetamorphic larvae showed coexpression in most of the DCX immunoreactive structures. No cells/fibers were found showing DCX and cytokeratins colocalization. The perikaryon of mature ganglion cells is DCX negative. The expression of DCX in sea lamprey retinas suggests that it could play roles in the migration of cells that differentiate in the metamorphosis, in the establishment of connections of ganglion cells and in the development of photoreceptors. Our results also suggest that the radial glia and retinal pigment epithelium cells of lampreys are neurogenic. Comparison of our observations with those reported in gnathostomes reveals similarities and interesting differences probably due to the peculiar development of the sea lamprey retina.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publication Artículo científico (JournalArticle)

Amber provenance as a Chrono-Cultural Proxy: Insights from FTIR analysis in the Iberian Peninsula

  • Garrido Cordero, J.A.
  • Odriozola, C.P.
  • Sousa, A.C.
  • Romero García, G.
  • Sánchez Gómez, D.
  • Blanes, J.M.M.
  • Lázarich González, María de la Concepción
  • Zambrana Vega, M.D.
  • Gonçalves, J.L.V.
In recent years, significant advancements have occurred in our comprehension of amber consumption patterns in the Iberian Peninsula. This progress stems from the increasing volume of FTIR data related to both archaeological and geological amber. Consequently, a chronological model has been established, delineating amber consumption in the Iberian Peninsula from the Late Paleolithic to the Iron Age. Broadly, local amber consumption has been minimal since the Paleolithic period. Sicilian amber makes its appearance in Iberia around the 5th millennium BCE and fades away in the 2nd millennium BCE, giving way to Baltic amber, which has remained the sole source since then. The well-defined chronological model, the abundance of FTIR provenance data, and the infrequent association of amber with absolute or relative dates prompt us to explore whether provenance can serve as a chrono-cultural proxy for amber beads. This study introduces new amber finds, presents fresh FTIR data on archaeological amber ornaments, and incorporates minor updates and bug fixes to the general catalog. It is the outcome of a thorough bibliographic review and on-site analysis and examination of the beads. The results obtained in this study enable the reconstruction of amber consumption throughout Iberian prehistory, drawing on 29 newly FTIR-analyzed ambers from 9 sites. Our findings expand the empirical foundation, facilitating the confirmation of diachronic changes in amber consumption. Importantly, they affirm that amber provenance can indeed be employed as a viable chrono-cultural proxy.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours

  • Groelly, Florian
  • Porru, Manuela
  • Zimmer, Jutta
  • Benainous, Hugo
  • De Visser, Yanti
  • Kosova, Anastasiya
  • Serra Elizalde, Violeta
BRCA2; DNA damage responses; Pyridostatin, BRCA2; Respostes al dany de l'ADN; Piridostatina, BRCA2; Respuestas al daño del ADN; Piridotatina, The cells with compromised BRCA1 or BRCA2 (BRCA1/2) function accumulate stalled replication forks, which leads to replication-associated DNA damage and genomic instability, a signature of BRCA1/2-mutated tumours. Targeted therapies against BRCA1/2-mutated tumours exploit this vulnerability by introducing additional DNA lesions. Because homologous recombination (HR) repair is abrogated in the absence of BRCA1 or BRCA2, these lesions are specifically lethal to tumour cells, but not to the healthy tissue. Ligands that bind and stabilise G-quadruplexes (G4s) have recently emerged as a class of compounds that selectively eliminate the cells and tumours lacking BRCA1 or BRCA2. Pyridostatin is a small molecule that binds G4s and is specifically toxic to BRCA1/2-deficient cells in vitro. However, its in vivo potential has not yet been evaluated. Here, we demonstrate that pyridostatin exhibits a high specific activity against BRCA1/2-deficient tumours, including patient-derived xenograft tumours that have acquired PARP inhibitor (PARPi) resistance. Mechanistically, we demonstrate that pyridostatin disrupts replication leading to DNA double-stranded breaks (DSBs) that can be repaired in the absence of BRCA1/2 by canonical non-homologous end joining (C-NHEJ). Consistent with this, chemical inhibitors of DNA-PKcs, a core component of C-NHEJ kinase activity, act synergistically with pyridostatin in eliminating BRCA1/2-deficient cells and tumours. Furthermore, we demonstrate that pyridostatin triggers cGAS/STING-dependent innate immune responses when BRCA1 or BRCA2 is abrogated. Paclitaxel, a drug routinely used in cancer chemotherapy, potentiates the in vivo toxicity of pyridostatin. Overall, our results demonstrate that pyridostatin is a compound suitable for further therapeutic development, alone or in combination with paclitaxel and DNA-PKcs inhibitors, for the benefit of cancer patients carrying BRCA1/2 mutations., Research in A.B. laboratory is supported by grants of Italian Association for Cancer Research (AIRC # 21579), Ministry of Health (CO 2019-12369662) and from IRCCS-Regina Elena Cancer Institute. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 722729 (F.J.G.). Research in M.T. laboratory is supported by Cancer Research UK (DRCPGM\100001), Medical Research Council and University of Oxford. A.R. received support from the UK Medical Research Council grant MC_PC_12006. V.S. received support from Instituto de Salud Carlos III (CPII19/00033, PI17/01080), GHD pink and the FERO Foundation.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Clinical consequences of BRCA2 hypomorphism

  • Castells-Roca, Laia
  • Gutierrez Enriquez, Sara
  • Bonache Real, Sandra
  • Carrasco López, Estela
  • Aza-Carmona, Miriam
  • Montalban Canudas, Gemma
  • Cruz Zambrano, Cristina
  • Llop Guevara, Alba
  • Serra Elizalde, Violeta
  • Diez Gibert, Orland
  • Balmaña Gelpí, Judith
  • Saura Manich, Cristina
  • Bogliolo, Massimo
Breast cancer; Cancer genetics, Cáncer de mama; Genética del cáncer, Càncer de mama; Genètica del càncer, The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly hereditary breast and ovarian cancer predisposition. For decades, the co-occurrence in trans with a clearly pathogenic variant led to assume that the other allele was benign. However, here we show a patient with biallelic BRCA2 (c.1813dup and c.7796 A > G) diagnosed at age 33 with FA after a hypertoxic reaction to chemotherapy during breast cancer treatment. After DNA damage, patient cells displayed intermediate chromosome fragility, reduced survival, cell cycle defects, and significantly decreased RAD51 foci formation. With a newly developed cell-based flow cytometric assay, we measured single BRCA2 allele contributions to HRR, and found that expression of the missense allele in a BRCA2 KO cellular background partially recovered HRR activity. Our data suggest that a hypomorphic BRCA2 allele retaining 37–54% of normal HRR function can prevent FA clinical phenotype, but not the early onset of breast cancer and severe hypersensitivity to chemotherapy.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

  • Serra Elizalde, Violeta
  • Wang, Anderson T.
  • Castroviejo Bermejo, Marta
  • Polanska, Urszula M.
  • Palafox Sánchez, Marta
  • Llop Guevara, Alba
  • Guzman Torres, Marta
  • Rodriguez Ferreiro, Olga
  • Grueso Gragera, Judit
  • Arribas López, Joaquin Vicente
  • Cortés Castan, Javier
  • Cruz Zambrano, Cristina
  • Balmaña Gelpí, Judith
  • Saura Manich, Cristina
  • Herencia Ropero, Andrea
Cáncer de mama y de ovario; Inhibición WEE1, Càncer de mama i d'ovari; Inhibició WEE1, Breast and ovarian cancer; WEE1 inhibition, Purpose: PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique approach to reverse both aspects of resistance. Recently, however, a PARPi/WEE1 inhibitor (WEE1i) combination demonstrated enhanced antitumor activity associated with the induction of replication stress, suggesting another approach to tackling PARPi resistance. Experimental Design: We analyzed breast and ovarian patient-derived xenoimplant models resistant to PARPi to quantify WEE1i and ATR inhibitor (ATRi) responses as single agents and in combination with PARPi. Biomarker analysis was conducted at the genetic and protein level. Metabolite analysis by mass spectrometry and nucleoside rescue experiments ex vivo were also conducted in patient-derived models. Results: Although WEE1i response was linked to markers of replication stress, including STK11/RB1 and phospho-RPA, ATRi response associated with ATM mutation. When combined with olaparib, WEE1i could be differentiated from the ATRi/olaparib combination, providing distinct therapeutic strategies to overcome PARPi resistance by targeting the replication stress response. Mechanistically, WEE1i sensitivity was associated with shortage of the dNTP pool and a concomitant increase in replication stress. Conclusions: Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi., This work was supported by the Spanish Instituto de Salud Carlos III (ISCIII), an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (FIS PI17/01080 to V. Serra, PI12/02606 to J. Balmaña); European Research Area-NET, Transcan-2 (AC15/00063), Asociación Española contra el Cáncer (AECC; LABAE16020PORTT), the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR; 2017 SGR 540), La Marató TV3 (654/C/2019), and ERAPERMED2019–215 to V. Serra. We also acknowledge the GHD-Pink program, the FERO Foundation, and the Orozco Family for supporting this study (to V. Serra). V. Serra was supported by the Miguel Servet Program (ISCIII; CPII19/00033); M. Castroviejo-Bermejo and C. Cruz (AIOC15152806CRUZ) by AECC; A. Herencia-Ropero by Generalitat de Catalunya-PERIS (SLT017/20/000081); M. Palafox by Juan de la Cierva (FJCI-2015–25412); A. Lau by AECC and Generalitat de Catalunya-PERIS (INVES20095LLOP, SLT002/16/00477); A. Gris-Oliver by FI-AGAUR (2015 FI_B 01075). This work was supported by Breast Cancer Research Foundation (BCRF-19–08), Instituto de Salud Carlos III Project Reference number AC15/00062, and the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer (to J. Arribas). The xenograft program in the Caldas laboratory was supported by Cancer Research UK and also received funding from an EU H2020 Network of Excellence (EuroCAN). The RPPA facility is funded by NCI #CA16672.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Castroviejo-Bermejo, Marta|||0000-0002-8540-5837
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Ibrahim, Yasir Hussein
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Bonache, Sandra|||0000-0002-7395-8143
  • Morancho, Beatriz|||0000-0003-3369-8647
  • Bruna, Alejandra|||0000-0003-1214-9665
  • Rueda, Oscar M.
  • Lai, Zhongwu|||0000-0002-1506-8222
  • Polanska, Urszula|||0000-0003-1017-594X
  • Jones, Gemma|||0000-0002-7567-681X
  • Kristel, Petra
  • de Bustos, L.
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Grueso, Judit|||0000-0003-1093-7940
  • Montalban, Gemma|||0000-0002-6958-4759
  • Caratù, Ginevra|||0000-0003-1085-8062
  • Mancuso, Francesco M.|||0000-0001-5499-6630
  • Fasani, Roberta|||0000-0003-1630-9988
  • Jiménez, Jose|||0000-0002-2576-1776
  • Howat, William J.
  • Dougherty, Brian|||0000-0002-0093-1142
  • Vivancos, Ana|||0000-0003-2888-6512
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Serres Creixams, Xavier|||0000-0001-8642-467X
  • Rubio Rodríguez, Isabel Teresa
  • Oaknin, Ana|||0000-0002-3592-7194
  • Cadogan, Elaine|||0000-0002-9757-8305
  • Barrett, J. Carl|||0000-0003-4042-9859
  • Caldas, Carlos|||0000-0003-3547-1489
  • Baselga Torres, Josep
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Jonkers, Jos|||0000-0002-9264-9792
  • Diez, Orland|||0000-0001-7339-0570
  • O'Connor, Mark J.|||0000-0003-1823-625X
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Serra, Violeta|||0000-0001-6620-1065
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). Their efficacy in germline BRCA1/2 (gBRCA1/2)-mutated metastatic breast cancers has been recently confirmed in clinical trials. Numerous mechanisms of PARPi resistance have been described, whose clinical relevance in gBRCA-mutated breast cancer is unknown. This highlights the need to identify functional biomarkers to better predict PARPi sensitivity. We investigated the in vivo mechanisms of PARPi resistance in gBRCA1 patient-derived tumor xenografts (PDXs) exhibiting differential response to PARPi. Analysis included exome sequencing and immunostaining of DNA damage response proteins to functionally evaluate HRR. Findings were validated in a retrospective sample set from gBRCA1/2-cancer patients treated with PARPi. RAD51 nuclear foci, a surrogate marker of HRR functionality, were the only common feature in PDX and patient samples with primary or acquired PARPi resistance. Consistently, low RAD51 was associated with objective response to PARPi. Evaluation of the RAD51 biomarker in untreated tumors was feasible due to endogenous DNA damage. In PARPi-resistant gBRCA1 PDXs, genetic analysis found no in-frame secondary mutations, but BRCA1 hypomorphic proteins in 60% of the models, TP53BP1 -loss in 20% and RAD51 -amplification in one sample, none mutually exclusive. Conversely, one of three PARPi-resistant gBRCA2 tumors displayed BRCA2 restoration by exome sequencing. In PDXs, PARPi resistance could be reverted upon combination of a PARPi with an ataxia-telangiectasia mutated (ATM) inhibitor. Detection of RAD51 foci in gBRCA tumors correlates with PARPi resistance regardless of the underlying mechanism restoring HRR function. This is a promising biomarker to be used in the clinic to better select patients for PARPi therapy. Our study also supports the clinical development of PARPi combinations such as those with ATM inhibitors.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation

  • Cedrés, Susana|||0000-0002-0648-7978
  • Felip, Enriqueta|||0000-0002-7620-0098
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Martinez de Castro, Ana
  • Pardo Aranda, Nuria
  • Navarro, Alejandro|||0000-0001-5903-270X
  • Martinez-Marti, Alex|||0000-0002-6714-9526
  • Remon, Jordin
  • Zeron-Medina, Jorge
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Miquel, Josep M.|||0000-0002-9262-4464
  • Sansano, Irene|||0000-0003-0188-5210
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Mancuso, Francesco M.|||0000-0001-5499-6630
  • Serra, Violeta|||0000-0001-6620-1065
  • Vivancos, Ana|||0000-0003-2888-6512
Heat shock proteins (HSPs) are molecular chaperones that maintain proteins in their correct conformation to ensure stability and protect carcinoma cells from apoptosis. HSP90 inhibitors (HSP90i) block multiple targets simultaneously, and despite responses in a selected population, no HSP90i have yet been approved. We present a patient with a lung tumor with an exceptional response to cisplatin/gemcitabine in combination with HSP90i, which nowadays continues with HSP90i maintenance after three years. Whole-exome sequencing of the lung tumor unveiled a BRCA1/2 deficiency mutational signature, and mutation analysis confirmed a germline BRCA1 mutation. The striking efficacy of HSP90i plus chemotherapy vs chemotherapy alone was reproduced in a patient-derived xenograft (PDX) model from a breast cancer patient with a BRCA1 mutation (mean tumor volume [SD], No. of tumors: vehicle 8.38 [7.07] mm 3, n = 3; HSP90i 4.18 [1.93] mm 3, n = 5; cisplatin plus gemcitabine 3.31 [1.95] mm 3, n = 5; cisplatin plus gemcitabine plus HSP90i 0.065 [0.076] mm 3, n = 6). This case and the PDX demonstrate the efficacy for therapeutic inhibition of HSP90 in a BRCA- mutated patient, opening a new potential avenue for better identifying patients who might benefit most from HSP90i.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A RAD51 assay feasible in routine tumor samples calls inhibitor response beyond BRCA mutation

  • Castroviejo-Bermejo, Marta|||0000-0002-8540-5837
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Ducy, Mandy
  • Ibrahim, Yasir Hussein
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Pellegrino, Benedetta
  • Bruna, Alejandra|||0000-0003-1214-9665
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Grueso, Judit|||0000-0003-1093-7940
  • Bonache, Sandra|||0000-0002-7395-8143
  • Moles-Fernández, Alejandro|||0000-0003-0252-6084
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Viaplana, Cristina|||0000-0001-8904-4330
  • Gómez Pardo, Patricia
  • Vidal, Marc
  • Peg, Vicente|||0000-0002-5203-6166
  • Serres Creixams, Xavier|||0000-0001-8642-467X
  • Dellaire, Graham
  • Simard, Jacques|||0000-0001-6906-3390
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Rubio, Isabel T.|||0000-0003-0035-0679
  • Dientsmann, Rodrigo
  • Barrett, J. Carl|||0000-0003-4042-9859
  • Caldas, Carlos|||0000-0003-3547-1489
  • Baselga Torres, Josep
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Déas, Olivier
  • Jonkers, Jos|||0000-0002-9264-9792
  • Masson, Jean-Yves
  • Cairo, Stefano
  • Judde, Jean-Gabriel
  • O'Connor, Mark J.|||0000-0003-1823-625X
  • Diez, Orland|||0000-0001-7339-0570
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Serra, Violeta|||0000-0001-6620-1065
Poly(-ribose) polymerase () inhibitors (i) are effective in cancers with defective homologous recombination repair (), including 1/2-related cancers. A test to identify additional -deficient tumors will help to extend their use in new indications. We evaluated the activity of the i olaparib in patient-derived tumor xenografts (s) from breast cancer () patients and investigated mechanisms of sensitivity through exome sequencing, 1 promoter methylation analysis, and immunostaining of proteins, including 51 nuclear foci. In an independent panel, the predictive capacity of the 51 score and the homologous recombination deficiency () score were compared. To examine the clinical feasibility of the 51 assay, we scored archival breast tumor samples, including 2-related hereditary cancers. The 51 score was highly discriminative of i sensitivity versus PARPi resistance in s and outperformed the genomic test. In clinical samples, all 2-related tumors were classified as -deficient by the 51 score. The functional biomarker 51 enables the identification of i-sensitive and broadens the population who may benefit from this therapy beyond 1/2-related cancers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

H3K4me1 marks DNA regions hypomethylated during aging in human stem and differentiated cells

  • Fernández, Agustín F.|||0000-0002-3792-4085
  • Fernández Bayón, Gustavo|||0000-0002-0763-0473
  • Urdinguio, Rocío G.|||0000-0003-2736-5758
  • Toraño, Estela G.
  • García, María G.
  • Carella, Antonella
  • Petrus-Reurer, Sandra
  • Ferrero, Cecilia
  • Martinez-Camblor, Pablo
  • Cubillo, Isabel
  • Garcia-Castro, Javier|||0000-0001-7604-1640
  • Delgado-Calle, Jesús
  • Pérez-Campo, Flor M.
  • Riancho, José A.|||0000-0003-0691-8755
  • Bueno, Clara|||0000-0003-1442-6216
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Mentink, Anouk
  • Mareschi, Katia
  • Claire, Fabian
  • Fagnani, Corrado
  • Medda, Emanuela
  • Toccaceli, Virgilia
  • Brescianini, Sonia
  • Moran, S.|||0000-0003-4192-8983
  • Esteller, M.|||0000-0003-4490-6093
  • Stolzing, Alexandra
  • de Boer, Jan
  • Nisticò, Lorenza
  • Stazi, Maria A.
  • Fraga, Mario|||0000-0001-8450-2603
In differentiated cells, aging is associated with hypermethylation of DNA regions enriched in repressive histone post-translational modifications. However, the chromatin marks associated with changes in DNA methylation in adult stem cells during lifetime are still largely unknown. Here, DNA methylation profiling of mesenchymal stem cells (MSCs) obtained from individuals aged 2 to 92 yr identified 18,735 hypermethylated and 45,407 hypomethylated CpG sites associated with aging. As in differentiated cells, hypermethylated sequences were enriched in chromatin repressive marks. Most importantly, hypomethylated CpG sites were strongly enriched in the active chromatin mark H3K4me1 in stem and differentiated cells, suggesting this is a cell type-independent chromatin signature of DNA hypomethylation during aging. Analysis of scedasticity showed that interindividual variability of DNA methylation increased during aging in MSCs and differentiated cells, providing a new avenue for the identification of DNA methylation changes over time. DNA methylation profiling of genetically identical individuals showed that both the tendency of DNA methylation changes and scedasticity depended on nongenetic as well as genetic factors. Our results indicate that the dynamics of DNA methylation during aging depend on a complex mixture of factors that include the DNA sequence, cell type, and chromatin context involved and that, depending on the locus, the changes can be modulated by genetic and/or external factors.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical consequences of BRCA2 hypomorphism

  • Castells Roca, Laia|||0000-0002-4604-9999
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Bonache, Sandra|||0000-0002-7395-8143
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Carrasco, Estela|||0000-0003-1964-7675
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Montalban, Gemma|||0000-0002-6958-4759
  • Muñoz-Subirana, N.
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Lasa, Adriana|||0000-0001-9957-9646
  • Serra, Violeta|||0000-0001-6620-1065
  • Diez, Orland|||0000-0001-7339-0570
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Surralles, Jordi|||0000-0002-4041-7519
The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly hereditary breast and ovarian cancer predisposition. For decades, the co-occurrence in trans with a clearly pathogenic variant led to assume that the other allele was benign. However, here we show a patient with biallelic BRCA2 (c.1813dup and c.7796 A.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

  • Serra, Violeta|||0000-0001-6620-1065
  • Wang, Anderson T.|||0000-0002-3571-5095
  • Castroviejo-Bermejo, Marta|||0000-0002-8540-5837
  • Polanska, Urszula|||0000-0003-1017-594X
  • Palafox, Marta|||0000-0002-1762-3250
  • Herencia-Ropero, Andrea|||0009-0002-9448-1484
  • Jones, Gemma|||0000-0002-7567-681X
  • Lai, Zhongwu|||0000-0002-1506-8222
  • Armenia, Joshua|||0000-0002-9005-7769
  • Michopoulos, Filippos|||0000-0002-3667-6147
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Brough, Rachel|||0000-0002-1862-7130
  • Gulati, Aditi|||0000-0001-7476-2524
  • Pettitt, Stephen|||0000-0003-3313-3857
  • Bulusu, Krishna C.|||0000-0002-5092-6640
  • Nikkila, Jenni|||0000-0003-1380-8781
  • Wilson, Zena|||0000-0001-8811-4069
  • Hughes, Adina|||0000-0002-5711-627X
  • Wijnhoven, Paul W.G.|||0000-0002-5489-3006
  • Ahmed, Ambar|||0000-0002-5890-5035
  • Bruna, Alejandra|||0000-0003-1214-9665
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Grueso, Judit|||0000-0003-1093-7940
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Lau, Alan|||0000-0003-1055-9812
  • Critchlow, Susan|||0000-0002-4647-8988
  • Dougherty, Brian|||0000-0002-0093-1142
  • Caldas, Carlos|||0000-0003-3547-1489
  • Mills, Gordon|||0000-0002-0144-9614
  • Barrett, J. Carl|||0000-0003-4042-9859
  • Forment, Josep V.|||0000-0002-7797-2583
  • Cadogan, Elaine|||0000-0002-9757-8305
  • Lord, Christopher J.|||0000-0002-3226-0515
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • O'Connor, Mark J.|||0000-0003-1823-625X
PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique approach to reverse both aspects of resistance. Recently, however, a PARPi/WEE1 inhibitor (WEE1i) combination demonstrated enhanced antitumor activity associated with the induction of replication stress, suggesting another approach to tackling PARPi resistance. We analyzed breast and ovarian patientderived xenoimplant models resistant to PARPi to quantify WEE1i and ATR inhibitor (ATRi) responses as single agents and in combination with PARPi. Biomarker analysis was conducted at the genetic and protein level. Metabolite analysis by mass spectrometry and nucleoside rescue experiments ex vivo were also conducted in patient-derived models. Although WEE1i response was linked to markers of replication stress, including STK11/RB1 and phospho-RPA, ATRi response associated with ATM mutation. When combined with olaparib, WEE1i could be differentiated from the ATRi/olaparib combination, providing distinct therapeutic strategies to overcome PARPi resistance by targeting the replication stress response. Mechanistically, WEE1i sensitivity was associated with shortage of the dNTP pool and a concomitant increase in replication stress. Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours

  • Groelly, Florian
  • Porru, Manuela
  • Zimmer, Jutta
  • Benainous, Hugo
  • De Visser, Yanti
  • Kosova, Anastasiya
  • Serra Elizalde, Violeta
BRCA2; DNA damage responses; Pyridostatin, BRCA2; Respostes al dany de l'ADN; Piridostatina, BRCA2; Respuestas al daño del ADN; Piridotatina, The cells with compromised BRCA1 or BRCA2 (BRCA1/2) function accumulate stalled replication forks, which leads to replication-associated DNA damage and genomic instability, a signature of BRCA1/2-mutated tumours. Targeted therapies against BRCA1/2-mutated tumours exploit this vulnerability by introducing additional DNA lesions. Because homologous recombination (HR) repair is abrogated in the absence of BRCA1 or BRCA2, these lesions are specifically lethal to tumour cells, but not to the healthy tissue. Ligands that bind and stabilise G-quadruplexes (G4s) have recently emerged as a class of compounds that selectively eliminate the cells and tumours lacking BRCA1 or BRCA2. Pyridostatin is a small molecule that binds G4s and is specifically toxic to BRCA1/2-deficient cells in vitro. However, its in vivo potential has not yet been evaluated. Here, we demonstrate that pyridostatin exhibits a high specific activity against BRCA1/2-deficient tumours, including patient-derived xenograft tumours that have acquired PARP inhibitor (PARPi) resistance. Mechanistically, we demonstrate that pyridostatin disrupts replication leading to DNA double-stranded breaks (DSBs) that can be repaired in the absence of BRCA1/2 by canonical non-homologous end joining (C-NHEJ). Consistent with this, chemical inhibitors of DNA-PKcs, a core component of C-NHEJ kinase activity, act synergistically with pyridostatin in eliminating BRCA1/2-deficient cells and tumours. Furthermore, we demonstrate that pyridostatin triggers cGAS/STING-dependent innate immune responses when BRCA1 or BRCA2 is abrogated. Paclitaxel, a drug routinely used in cancer chemotherapy, potentiates the in vivo toxicity of pyridostatin. Overall, our results demonstrate that pyridostatin is a compound suitable for further therapeutic development, alone or in combination with paclitaxel and DNA-PKcs inhibitors, for the benefit of cancer patients carrying BRCA1/2 mutations., Research in A.B. laboratory is supported by grants of Italian Association for Cancer Research (AIRC # 21579), Ministry of Health (CO 2019-12369662) and from IRCCS-Regina Elena Cancer Institute. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 722729 (F.J.G.). Research in M.T. laboratory is supported by Cancer Research UK (DRCPGM\100001), Medical Research Council and University of Oxford. A.R. received support from the UK Medical Research Council grant MC_PC_12006. V.S. received support from Instituto de Salud Carlos III (CPII19/00033, PI17/01080), GHD pink and the FERO Foundation.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Clinical consequences of BRCA2 hypomorphism

  • Castells-Roca, Laia
  • Gutierrez Enriquez, Sara
  • Bonache Real, Sandra
  • Carrasco López, Estela
  • Aza-Carmona, Miriam
  • Montalban Canudas, Gemma
  • Cruz Zambrano, Cristina
  • Llop Guevara, Alba
  • Serra Elizalde, Violeta
  • Diez Gibert, Orland
  • Balmaña Gelpí, Judith
  • Saura Manich, Cristina
  • Bogliolo, Massimo
Breast cancer; Cancer genetics, Cáncer de mama; Genética del cáncer, Càncer de mama; Genètica del càncer, The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly hereditary breast and ovarian cancer predisposition. For decades, the co-occurrence in trans with a clearly pathogenic variant led to assume that the other allele was benign. However, here we show a patient with biallelic BRCA2 (c.1813dup and c.7796 A > G) diagnosed at age 33 with FA after a hypertoxic reaction to chemotherapy during breast cancer treatment. After DNA damage, patient cells displayed intermediate chromosome fragility, reduced survival, cell cycle defects, and significantly decreased RAD51 foci formation. With a newly developed cell-based flow cytometric assay, we measured single BRCA2 allele contributions to HRR, and found that expression of the missense allele in a BRCA2 KO cellular background partially recovered HRR activity. Our data suggest that a hypomorphic BRCA2 allele retaining 37–54% of normal HRR function can prevent FA clinical phenotype, but not the early onset of breast cancer and severe hypersensitivity to chemotherapy.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

  • Serra Elizalde, Violeta
  • Wang, Anderson T.
  • Castroviejo Bermejo, Marta
  • Polanska, Urszula M.
  • Palafox Sánchez, Marta
  • Llop Guevara, Alba
  • Guzman Torres, Marta
  • Rodriguez Ferreiro, Olga
  • Grueso Gragera, Judit
  • Arribas López, Joaquin Vicente
  • Cortés Castan, Javier
  • Cruz Zambrano, Cristina
  • Balmaña Gelpí, Judith
  • Saura Manich, Cristina
  • Herencia Ropero, Andrea
Cáncer de mama y de ovario; Inhibición WEE1, Càncer de mama i d'ovari; Inhibició WEE1, Breast and ovarian cancer; WEE1 inhibition, Purpose: PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique approach to reverse both aspects of resistance. Recently, however, a PARPi/WEE1 inhibitor (WEE1i) combination demonstrated enhanced antitumor activity associated with the induction of replication stress, suggesting another approach to tackling PARPi resistance. Experimental Design: We analyzed breast and ovarian patient-derived xenoimplant models resistant to PARPi to quantify WEE1i and ATR inhibitor (ATRi) responses as single agents and in combination with PARPi. Biomarker analysis was conducted at the genetic and protein level. Metabolite analysis by mass spectrometry and nucleoside rescue experiments ex vivo were also conducted in patient-derived models. Results: Although WEE1i response was linked to markers of replication stress, including STK11/RB1 and phospho-RPA, ATRi response associated with ATM mutation. When combined with olaparib, WEE1i could be differentiated from the ATRi/olaparib combination, providing distinct therapeutic strategies to overcome PARPi resistance by targeting the replication stress response. Mechanistically, WEE1i sensitivity was associated with shortage of the dNTP pool and a concomitant increase in replication stress. Conclusions: Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi., This work was supported by the Spanish Instituto de Salud Carlos III (ISCIII), an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (FIS PI17/01080 to V. Serra, PI12/02606 to J. Balmaña); European Research Area-NET, Transcan-2 (AC15/00063), Asociación Española contra el Cáncer (AECC; LABAE16020PORTT), the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR; 2017 SGR 540), La Marató TV3 (654/C/2019), and ERAPERMED2019–215 to V. Serra. We also acknowledge the GHD-Pink program, the FERO Foundation, and the Orozco Family for supporting this study (to V. Serra). V. Serra was supported by the Miguel Servet Program (ISCIII; CPII19/00033); M. Castroviejo-Bermejo and C. Cruz (AIOC15152806CRUZ) by AECC; A. Herencia-Ropero by Generalitat de Catalunya-PERIS (SLT017/20/000081); M. Palafox by Juan de la Cierva (FJCI-2015–25412); A. Lau by AECC and Generalitat de Catalunya-PERIS (INVES20095LLOP, SLT002/16/00477); A. Gris-Oliver by FI-AGAUR (2015 FI_B 01075). This work was supported by Breast Cancer Research Foundation (BCRF-19–08), Instituto de Salud Carlos III Project Reference number AC15/00062, and the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer (to J. Arribas). The xenograft program in the Caldas laboratory was supported by Cancer Research UK and also received funding from an EU H2020 Network of Excellence (EuroCAN). The RPPA facility is funded by NCI #CA16672.